Key result
Esmolol and tecadenoson (75 μg) significantly prolonged the absolute refractory periods of the slow and fast pathways of the AV node in patients with atrial fibrillation (P<0.05).
Why the study?
Do rate-control drugs (tecadenoson and esmolol) alter AV nodal properties as assessed by a novel noninvasive ECG-based method in patients with atrial fibrillation?
RCT (n=14)
Randomly assigned
Do rate-control drugs (tecadenoson and esmolol) alter AV nodal properties as assessed by a novel noninvasive ECG-based method in patients with atrial fibrillation?
Absolute Event Rate: 409% vs 387%
p-value: p=<0.05
A novel noninvasive ECG-based method can successfully detect expected changes in AV nodal refractory periods during administration of rate-control drugs in patients with atrial fibrillation.
No takes yet. Share an insight, caveat, or question.
Enables noninvasive ECG monitoring of AV nodal effects from rate-control drugs in AF; extends validation of the method for clinical and research use.
Corino et al. (2014) conducted an RCT in Atrial fibrillation (n=14). Tecadenoson and esmolol vs. Baseline was evaluated on Absolute refractory period of the slow pathway (aRPs) during esmolol infusion (p=<0.05). Esmolol and tecadenoson (75 μg) significantly prolonged the absolute refractory periods of the slow and fast pathways of the AV node in patients with atrial fibrillation (P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: